| __timestamp | Amgen Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 26684000 |
| Thursday, January 1, 2015 | 4846000000 | 29829000 |
| Friday, January 1, 2016 | 5062000000 | 39578000 |
| Sunday, January 1, 2017 | 4870000000 | 43277000 |
| Monday, January 1, 2018 | 5332000000 | 48645000 |
| Tuesday, January 1, 2019 | 5150000000 | 52934000 |
| Wednesday, January 1, 2020 | 5730000000 | 61349000 |
| Friday, January 1, 2021 | 5368000000 | 127125000 |
| Saturday, January 1, 2022 | 5414000000 | 136106000 |
| Sunday, January 1, 2023 | 6179000000 | 133175999 |
| Monday, January 1, 2024 | 7096000000 |
Infusing magic into the data realm
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Amgen Inc. and HUTCHMED (China) Limited have showcased contrasting SG&A spending patterns.
Amgen, a titan in the biotech industry, has consistently increased its SG&A expenses, peaking at approximately $6.2 billion in 2023. This represents a 31% increase from 2014, reflecting its aggressive market strategies and expansion efforts.
Conversely, HUTCHMED, a rising star in the Chinese pharmaceutical landscape, has seen its SG&A expenses grow by nearly 400% over the same period, albeit from a much smaller base. This rapid increase underscores its commitment to scaling operations and enhancing market presence.
These spending patterns highlight the diverse strategies employed by established and emerging players in the pharmaceutical sector.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Amgen Inc. vs Pharming Group N.V. Trends and Insights
Cost of Revenue Trends: Amgen Inc. vs HUTCHMED (China) Limited
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Analyzing R&D Budgets: Amgen Inc. vs HUTCHMED (China) Limited
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.